X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
blinatumomab (341) 341
index medicus (215) 215
humans (167) 167
oncology (142) 142
hematology (126) 126
therapy (105) 105
cancer (99) 99
acute lymphoblastic-leukemia (95) 95
chemotherapy (95) 95
immunotherapy (94) 94
acute lymphoblastic leukemia (92) 92
leukemia (81) 81
minimal residual disease (77) 77
adult patients (61) 61
antibodies, bispecific - therapeutic use (56) 56
t cells (52) 52
acute lymphocytic leukemia (51) 51
adult (49) 49
animals (49) 49
male (49) 49
inotuzumab ozogamicin (47) 47
antineoplastic agents - therapeutic use (46) 46
care and treatment (46) 46
lymphocytes (46) 46
t-lymphocytes - immunology (46) 46
female (45) 45
pharmacology & pharmacy (44) 44
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (40) 40
t-cells (39) 39
lymphocytes t (38) 38
bispecific antibodies (37) 37
cytokine release syndrome (37) 37
antibodies (35) 35
immunology (35) 35
free survival (34) 34
antigens (33) 33
middle aged (33) 33
term-follow-up (33) 33
transplantation (33) 33
acute lymphatic leukemia (32) 32
b-lineage (32) 32
relapse (32) 32
research (32) 32
aged (31) 31
cytotoxicity (31) 31
rituximab (31) 31
acute lymphocytic-leukemia (30) 30
mice (30) 30
phase-ii (30) 30
cd19 (29) 29
medicine, research & experimental (29) 29
patients (29) 29
survival (29) 29
lymphatic leukemia (28) 28
monoclonal antibodies (28) 28
children (27) 27
cytokines (27) 27
immunotherapy - methods (27) 27
medicine & public health (27) 27
precursor cell lymphoblastic leukemia-lymphoma - therapy (27) 27
treatment outcome (27) 27
antibody (26) 26
precursor cell lymphoblastic leukemia-lymphoma - immunology (26) 26
article (25) 25
adults (24) 24
antigens, cd19 - immunology (24) 24
clinical trials (24) 24
expression (24) 24
lymphoma (24) 24
remission (24) 24
antibodies, bispecific - immunology (23) 23
antibodies, bispecific - pharmacology (23) 23
clinical trials as topic (23) 23
health aspects (23) 23
hyper-cvad (23) 23
recurrence (23) 23
young adult (23) 23
activation (22) 22
antibody blinatumomab (22) 22
bite (22) 22
cd3 complex - immunology (22) 22
cell line, tumor (22) 22
hemic and lymphatic diseases (22) 22
precursor cell lymphoblastic leukemia-lymphoma - pathology (22) 22
remission induction (22) 22
stem cells (22) 22
toxicity (22) 22
tumors (22) 22
viral antibodies (22) 22
abridged index medicus (21) 21
antibodies, monoclonal - therapeutic use (21) 21
bispecific antibody (21) 21
lymphomas (21) 21
pediatrics (21) 21
philadelphia chromosome (21) 21
precursor cell lymphoblastic leukemia-lymphoma - mortality (21) 21
prognosis (21) 21
review (21) 21
single-arm (21) 21
single-chain antibody (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2018, Volume 24, Issue 19, pp. 4785 - 4797
Purpose: Despite promising clinical activity, T-cell-engaging therapies including T-cell bispecific antibodies (TCB) are associated with severe side effects... 
B-CELL LYMPHOMA | TCB | MODELS | ONCOLOGY | IBRUTINIB | NON-HODGKIN-LYMPHOMA | ANTIBODY | BLINATUMOMAB | COMBINATION | CHEMOTHERAPY
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 03/2014, Volume 74, Issue 5, pp. 1349 - 1360
The ability of human gamma delta T cells from healthy donors to kill pancreatic ductal adenocarcinoma (PDAC) in vitro and in vivo in immunocompromised mice... 
BREAST-CANCER | INTERLEUKIN-2 | ZOLEDRONATE | TRASTUZUMAB | ONCOLOGY | IMMUNOTHERAPY | ADENOCARCINOMA | IN-VIVO | BLINATUMOMAB | EXPRESSION | LYMPHOCYTES
Journal Article
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, ISSN 0027-8874, 07/2019, Volume 111, Issue 7, pp. 646 - 654
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary new form of immunotherapy for the treatment of hematologic malignancies. The two primary... 
BIOMARKERS | CHIMERIC ANTIGEN RECEPTORS | THERAPY | MANAGEMENT | B-CELL | ONCOLOGY | IMMUNOTHERAPY | REMISSIONS | BRAIN-BARRIER DISRUPTION | TOXICITY | BLINATUMOMAB
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2018, Volume 378, Issue 5, pp. 449 - 459
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 07/2019, Volume 79, Issue 13, pp. 3372 - 3382
Acute myeloid leukemia (AML) is a high-risk disease with a poor prognosis, particularly in elderly patients. Because current AML treatment relies primarily on... 
B-CELLS | AML | ONCOLOGY | MONOCLONAL-ANTIBODY | GENERATION | BLINATUMOMAB | SORTASE | ELDERLY-PATIENTS
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 07/2019, Volume 25, Issue 13, pp. 3921 - 3933
Purpose: Despite advances in the treatment of multiple myeloma, new therapies are needed to induce more profound clinical responses. T-cell-redirected lysis... 
DARATUMUMAB | CRITERIA | EFFICACY | ONCOLOGY | RESPONSE ASSESSMENT | CD38 EXPRESSION | BLINATUMOMAB | MINIMAL RESIDUAL DISEASE
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 04/2018, Volume 65, pp. 87 - 95
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 10/2018, Volume 24, Issue 20, pp. 4988 - 4996
Purpose: AMG 211, a bispecific T-cell engager (BiTE) antibody construct, targets carcinoembryonic antigen (CEA) and the CD3 epsilon subunit of the human T-cell... 
ONCOLOGY | ADENOCARCINOMAS | GROWTH | LYMPHOMA | BIODISTRIBUTION | CHAIN ANTIBODY CONSTRUCTS | CARCINOEMBRYONIC ANTIGEN | BLINATUMOMAB | INDUCTION | BITE(R) | CANCER
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2014, Volume 371, Issue 16, pp. 1507 - 1517
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2019, Volume 19, pp. S60 - S62
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2017, Volume 28, Issue 8, pp. 2009 - 2012
Journal Article
Molecular cancer therapeutics, ISSN 1535-7163, 02/2019, Volume 18, Issue 2, pp. 312 - 322
Immunotherapy of cancer with CD3-targeting bispecific antibodies (CD3 bsAb) is a fast developing field, and multiple tumor-associated antigens (TAA) are... 
BISPECIFIC ANTIBODIES | REGRESSION | GAMMA | RECOGNITION | EFFICACY | ONCOLOGY | MOUSE | GENERATION | BLINATUMOMAB | BINDING | T-CELLS
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6447 - 6458
Purpose: The response to cancer immune therapy is dependent on endogenous tumor-reactive T cells. To bypass this requirement, CD3-bispecific antibodies have... 
TUMOR-INFILTRATING LYMPHOCYTES | TRIAL | THERAPY | CXC CHEMOKINE | TRASTUZUMAB | ONCOLOGY | CYTOKINE RELEASE SYNDROME | FREE SURVIVAL | REMISSIONS | BLINATUMOMAB | HER2-POSITIVE BREAST-CANCER
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 04/2019, Volume 25, Issue 4, pp. 625 - 638
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were... 
Immune effector cell | Cytokine release syndrome | Neurotoxicity | CAR T cell therapy | Cellular immunotherapy | Consensus grading | CART cell therapy | ACTIVATION | MANAGEMENT | IMMUNOLOGY | CORNELL ASSESSMENT | TRANSPLANTATION | THERAPY | B-CELL | DELIRIUM | REMISSIONS | CAR-T-CELLS | BLINATUMOMAB | HEMATOLOGY | Cytokines
Journal Article